Related Experiment Video
Updated: Dec 29, 2025
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
826
Dulaglutide: A Review in Type 2 Diabetes
1Springer Nature, Mairangi Bay, Private Bag 65901, Auckland, 0754, New Zealand. demail@springer.com.
Drugs
|February 1, 2020
Summary
Dulaglutide, a weekly injection for type 2 diabetes, effectively controls blood sugar and reduces major adverse cardiac events in adults. It is well-tolerated, even in high-risk patients.
Area of Science:
- Endocrinology
- Pharmacology
- Cardiology
Background:
- Type 2 diabetes (T2D) is a chronic metabolic disorder requiring effective management.
- Subcutaneous dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist approved for T2D treatment.
- Patients with T2D often have comorbidities, including cardiovascular disease and chronic kidney disease.
Purpose of the Study:
- To evaluate the efficacy and safety of dulaglutide in adults with inadequately controlled T2D.
- To assess the cardiovascular outcomes of dulaglutide in the REWIND trial.
- To determine the role of dulaglutide in managing T2D, including in high-risk populations.
Main Methods:
- Systematic review of clinical trials and real-world data on dulaglutide use in T2D.
- Analysis of data from the REWIND cardiovascular outcomes trial.
- Inclusion of data from diverse patient groups, including those with obesity, elderly patients, and those with CKD or CV disease.
Main Results:
- Dulaglutide demonstrated effective and generally well-tolerated glycemic control as monotherapy or add-on therapy.
- The REWIND trial showed a significant reduction in major adverse cardiac events (MACE) with dulaglutide.
- Benefits were observed across various patient subgroups, including high-risk individuals.
Conclusions:
- Once-weekly subcutaneous dulaglutide is an effective treatment option for adults with inadequately controlled T2D.
- Dulaglutide offers significant cardiovascular benefits, reducing the risk of MACE.
- Its favorable profile, including durable glycemic efficacy, weight management, and low hypoglycemia risk, makes it a valuable tool in T2D management.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
767
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
767
01:06Oral Hypoglycemic Agents: Glinides
514
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
514
01:23Dipeptidyl Peptidase 4 Inhibitors
497
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
497
01:22Diabetes Mellitus: Type 2 and Gestational
4.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.2K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
536
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
536
01:17Oral Hypoglycemic Agents: Sulfonylureas
674
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
674